Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s10585-021-10083-1 http://scihub22266oqcxt.onion/10.1007/s10585-021-10083-1 33759009!7987238!33759009     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Exp+Metastasis 2021 ; 38 (3): 257-261 Nephropedia Template TP {{tp|p=33759009|t=2021. Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis?|pdf=|usr=}}{{33759009}} gab.com Text Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis JO: Clin Exp Metastasis http://www.kidney.de/pget.php?&tw=1&pmid=33759009 #FOAvip Cancer patients represent a vulnerable cohort during the Sars-CoV-2 pandemic. Oncological societies have generated a plethora of recommendations, but precise instructions about routine oncological procedures remain scarce. Here, we report on local COVID-19 protection measures established in an interdisciplinary approach at a tertiary care center during the first wave of the pandemia in Germany. Following these measures, no additional morbidity or mortality during oncological procedures was observed, and no nosocomial infections were registered. However, Validation of our measures is outstanding and regional SARS-CoV-2 prevalence was low. However, specific oncological measures might be important to ensure optimal oncological results, especially for advanced cancer stages during this and future pandemia. In the future, communication about these measures might be crucial to a cancer patient s assigned network to reduce the danger of excess mortality within the second wave of the COVID-19 pandemic. Twit Text FOAVip Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis ????Clin Exp Metastasis http://www.kidney.de/pget.php?&tw=1&pmid=33759009 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33759009 #FOAvip English Wikipedia <ref>{{Cite pmid|33759009}}</ref> Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis? #MMPMID33759009 Ivanyi P; Park-Simon T; Christiansen H; Gutzmer R; Vogel A; Heuser M; Golpon H; Hillemanns P; Haier J Clin Exp Metastasis 2021[Jun]; 38 (3): 257-261 PMID33759009show ga Cancer patients represent a vulnerable cohort during the Sars-CoV-2 pandemic. Oncological societies have generated a plethora of recommendations, but precise instructions about routine oncological procedures remain scarce. Here, we report on local COVID-19 protection measures established in an interdisciplinary approach at a tertiary care center during the first wave of the pandemia in Germany. Following these measures, no additional morbidity or mortality during oncological procedures was observed, and no nosocomial infections were registered. However, Validation of our measures is outstanding and regional SARS-CoV-2 prevalence was low. However, specific oncological measures might be important to ensure optimal oncological results, especially for advanced cancer stages during this and future pandemia. In the future, communication about these measures might be crucial to a cancer patient s assigned network to reduce the danger of excess mortality within the second wave of the COVID-19 pandemic. |COVID-19/epidemiology/*prevention & control/transmission/virology[MESH] |Germany/epidemiology[MESH] |Humans[MESH] |Infection Control/*methods/organization & administration/standards[MESH] |Medical Oncology/*methods/organization & administration/standards[MESH] |Neoplasms/complications/*immunology[MESH] |Pandemics/*prevention & control/statistics & numerical data[MESH] |Prevalence[MESH] |SARS-CoV-2/immunology/pathogenicity[MESH]Protective measures for patients with advanced cancer during the Sars-(epmc).pdf DeepDyve Pubget Overpricing